Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
Prelude Therapeutics表示PRT3789在一期临床试验中显示出“令人鼓舞的迹象”;股价下跌
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册